Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Novartis - Optimising patient outcomes and quality of life in HR+, HER2– ABC

Emerging role of biomarker-driven therapy with PI3K inhibitors

Date

29 Sep 2019

Session

Novartis - Optimising patient outcomes and quality of life in HR+, HER2– ABC

Presenters

Lesley Fallowfield

Authors

Y. Lu1, L. Fallowfield2

Author affiliations

  • 1 Oncology, National Taiwan University Hospital, Taipei/TW
  • 2 Brighton and Sussex Medical School, University of Sussex, BN1 9PX - Brighton/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introduction

Presenter: Nadia Harbeck

Session: Novartis - Optimising patient outcomes and quality of life in HR+, HER2– ABC

Resources:

Webcast

Panelists

Presenter: Yen-Shen Lu

Session: Novartis - Optimising patient outcomes and quality of life in HR+, HER2– ABC

Resources:

Webcast

Panelists

Presenter: Nadia Harbeck

Session: Novartis - Optimising patient outcomes and quality of life in HR+, HER2– ABC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.